Cove Neurosciences Inc.

In the clinical trial setting, only 8.2% of drugs tested for neurological diseases reach the clinical setting, relative to 15% of all drugs overall. This is largely due to the lack of biomarkers to characterize the heterogeneity of patients, as well as variable response to therapeutics. Accordingly, there is a critical unmet need for biomarkers…